Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoglycemia

F J Service1

  • 1Division of Endocrinology, Metabolism and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.

Endocrinology and Metabolism Clinics of North America
|January 16, 1998
PubMed
Summary
This summary is machine-generated.

Diagnosing hypoglycemia involves assessing for drugs or illness and using specific criteria. Key indicators for insulin-mediated hypoglycemia include elevated insulin, C-peptide, and proinsulin levels, with a glucagon response test.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.

Diabetes care·2006
Same author

Glycated hemoglobin in insulinoma.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2004
Same author

Combination therapy for type 2 diabetes.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2004
Same author

Preoperative detection of pancreatic insulinomas on multiphasic helical CT.

AJR. American journal of roentgenology·2003
Same author

Insulinoma in chronic renal failure: a case report.

The Journal of clinical endocrinology and metabolism·2002
Same author

The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial.

Diabetologia·2001
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Area of Science:

  • Endocrinology
  • Clinical Diagnostics

Background:

  • Hypoglycemic disorders necessitate a high index of suspicion and thorough patient evaluation.
  • Diagnosing these conditions is challenging, particularly in seemingly healthy individuals experiencing neuroglycopenia.

Purpose of the Study:

  • To outline diagnostic criteria for identifying insulin-mediated hypoglycemia.
  • To emphasize the importance of drug screening, specifically for sulfonylureas, in hypoglycemic patients.

Main Methods:

  • Utilizing established diagnostic criteria for hypoglycemia assessment.
  • Employing radioimmunoassay and ICMA for measuring plasma insulin, C-peptide, and proinsulin.
  • Administering intravenous glucagon during hypoglycemia to assess glucose response and testing plasma for beta-hydroxybutyrate and sulfonylureas.

Related Experiment Videos

Main Results:

  • Specific thresholds for plasma insulin (>6 microU/mL), C-peptide (>200 pmol/L), and proinsulin (>5 pmol/L) indicate insulin mediation.
  • A low beta-hydroxybutyrate level (<2.7 mmol/L) and a significant glucose increase (>25 mg/dL) post-glucagon further support this diagnosis.
  • Detection of sulfonylureas, including second-generation drugs, is crucial.

Conclusions:

  • A methodical approach using defined criteria aids in diagnosing hypoglycemic disorders.
  • Accurate measurement of specific biomarkers and drug screening are essential for confirming insulin mediation and identifying causative agents.